B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

KCNJ10

MOLECULAR TARGET

potassium inwardly rectifying channel subfamily J member 10

UniProt: P78508NCBI Gene: 37661 compounds

KCNJ10 (potassium inwardly rectifying channel subfamily J member 10) is targeted by 1 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting KCNJ10

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Nortriptyline0.691

About KCNJ10 as a Drug Target

KCNJ10 (potassium inwardly rectifying channel subfamily J member 10) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 1 compounds with documented KCNJ10 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

KCNJ10 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.